Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424258 | 1.00 | POLB (0.46) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL18821238 | 0.79 | POLB (0.47) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL16925439 | 0.79 | OPRM1 (0.40) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL23388812 | 0.78 | POLB (0.46) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL156753 | 0.78 | POLB (0.46) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL29095734 | 0.78 | POLB (0.46) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL27722462 | 0.77 | POLB (0.45) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL4152272 | 0.76 | CYP2C19 (0.42) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL3268225 | 0.75 | POLB (0.43) | POLBOPRM1SMN1; SMN2ATMMEN1 | |
| SCHEMBL12490897 | 0.74 | GRIN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563789-B1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LTD (GB) | 2015-05-20 | — | — | EP | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-8633319-B2 | 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors | GLAXO GROUP LIMITED (GB) | 2014-01-21 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| WO-2011134971-A1 | 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040984-A1 | 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | SYK, BTK, LYN | POLB 4453/4885OPRM1 3551/4885SMN1; SMN2 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.